Trial reportBlood2019
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Abstract readClinical Trial, Phase IIILetterRandomized Controlled Trial
In one paragraph
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Trial
- Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.Nature communications · 2023Trial
- TP53 mutations and IGHV in naïve chronic lymphocytic leukemia: retrospective analysis of data from a Spanish collaborative network.International journal of hematology · 2026Article
- Review
- Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.Blood advances · 2025Article
- Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Molecular techniques in haematopathology: what and how?Histopathology · 2025Review
- Review
- Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.Current oncology reports · 2024Review
- Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.Journal of hematology & oncology · 2023Review
- Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.Blood cancer journal · 2023Article
- Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.Future oncology (London, England) · 2022Review
- Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemia.Frontiers in oncology · 2022Article
- Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.Frontiers in oncology · 2022Article
- Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?Leukemia · 2021Article
- Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Honokiol-Chlorambucil Co-Prodrugs Selectively Enhance the Killing Effect through STAT3 Binding on Lymphocytic Leukemia CellsACS omega · 2020Article
- Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.Future science OA · 2019Article
- Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.Haematologica · 2019Review
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Anton W LangerakDepartment of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-2078-3220
Matthias RitgenDepartment of Hematology, University of Schleswig-Holstein, Kiel, Germany.
Valentin GoedeOncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
Sandra RobrechtGerman CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Jasmin BahloGerman CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Kirsten FischerGerman CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Michael SteurerDivision of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Marek TrněnýCharles University Hospital, Prague, Czech Republic.ORCID 0000-0002-6952-6073
Stephen P MulliganRoyal North Shore Hospital, University of Sydney, Sydney, Australia.
Ulrich J M MeyKantonsspital Graubünden, Chur, Switzerland.
Kerstin TrunzerPharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0001-5559-1061
Günter Fingerle-RowsonPharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Kathryn HumphreyPharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom.
Stephan StilgenbauerInternal Medicine III, University of Ulm, Ulm, Germany.
Sebastian BöttcherDepartment of Hematology, University of Schleswig-Holstein, Kiel, Germany.
Monika BrüggemannDepartment of Hematology, University of Schleswig-Holstein, Kiel, Germany.ORCID 0000-0001-5514-5010
Michael HallekGerman CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Michael KnebaDepartment of Hematology, University of Schleswig-Holstein, Kiel, Germany.
Jacques J M van DongenDepartment of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-3650-7087
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChlorambucilComorbidityHumansLeukemia, Lymphocytic, Chronic, B-CellMiddle AgedNeoplasm, ResidualPrognosisProspective StudiesRituximabAntibodies, Monoclonal, HumanizedAntineoplastic AgentsChlorambucilobinutuzumabRituximab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.